Novo Nordisk's once-daily injection

Victoza (liraglutide) received FDA

approval to treat some adults with type 2 diabetes, the regulatory

agency announced Monday. The company expects the treatment to be

on the US market within weeks.

The FDA stated that the approval of the GLP-1 analogue came with

several post-marketing requirements, including a cardiovascular safety

study to examine the cardiovascular safety of Victoza in a higher risk

population, and a 5-year epidemiological study to "evaluate thyroid and other cancer risks as well as risks for

hypoglycaemia, pancreatitis, and allergic reactions